Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31047777 | 0.87 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL28458423 | 0.87 | KMT2A (0.44) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL26941528 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL27872882 | 0.87 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8178563 | 0.86 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8013142 | 0.86 | KMT2A (0.43) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31540857 | 0.85 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4263538 | 0.85 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4284636 | 0.84 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2CA1 | |
| Hydrochloric Acid SCHEMBL31540856 | 0.84 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1556384-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7084270-B2 | Pyrimido compounds having antiproliferative activity | HOFFMAN-LA ROCHE INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1556384-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004018472-A2 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-04 | — | — | WO | disclosed |
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038995-A1 | Pyrimido compounds having antiproliferative activity | LCK, FGFR1, FGFR3 | KMT2A 1309/4885FABP5 2330/4885FABP7 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.